The Berkland lab focuses on developing new therapeutics and biomaterials for improving human health
Cory Berkland’s lab studies pharmaceuticals and biomaterials with a particular emphasis on molecular design, drug formulation, and transport in the human body. Professor Berkland is a co-founder of Orbis Biosciences (acquired by Adare Pharmaceuticals), Savara Pharmaceuticals (NASDAQ:SVRA), Bond Biosciences, and several other start-ups. Professor Berkland is currently CEO of Bond Biosciences and is an executive and chairman of the board for Kinimmune and Axioforce.